Advisory Panel For Bristol's Yervoy Is Called Off, Which May Bode Well
This article was originally published in The Pink Sheet Daily
Executive Summary
After extending the review, FDA says it no longer needs ODAC's advice on the second-line melanoma treatment, which looks like a good sign for approval.
You may also be interested in...
Yervoy Cuts To The Head Of The Line: Ipilimumab Has Unrestricted Label
Bristol-Myers Squibb's immunotherapy Yervoy (ipilimumab) will enter the market positioned for wide use, with a broad label for its approval for metastatic melanoma and positive Phase III results for front-line patients.
Yervoy Cuts To The Head Of The Line: Ipilimumab Has Unrestricted Label
Bristol-Myers Squibb's immunotherapy Yervoy (ipilimumab) will enter the market positioned for wide use, with a broad label for its approval for metastatic melanoma and positive Phase III results for front-line patients.
Plexxikon, Roche Near Catalyst For BRAF Inhibitor In Melanoma
As its melanoma drug advances in the clinic, Plexxikon obtains rights to co-promote it in the U.S.